Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,604
Out of 4,983 analysts
141
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $11.75 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $29.42 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $575.06 | +47.81% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.08 | +1,566.67% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.71 | +3,408.77% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.37 | +279.75% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $9.13 | +272.40% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $143.68 | +127.59% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $3.02 | +893.38% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $17.63 | +3,121.78% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $391.36 | -28.20% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.83 | +182.69% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $0.95 | +10,208.19% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $273.09 | +8.02% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $110.86 | -22.42% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $31.99 | +50.05% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.95 | +331.65% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $36.72 | +96.08% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.23 | +306.50% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $83.90 | +19.19% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $197.24 | +1.91% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $59.69 | +42.40% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $12.52 | +155.59% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $18.10 | +1,098.90% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $19.39 | +147.55% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.60 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $461.24 | -66.61% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $53.94 | +115.05% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $4.52 | +2,245.13% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.27 | +128.20% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $210.04 | -60.96% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $397.97 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.54 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.75
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.42
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $575.06
Upside: +47.81%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.08
Upside: +1,566.67%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.71
Upside: +3,408.77%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.37
Upside: +279.75%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $9.13
Upside: +272.40%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $143.68
Upside: +127.59%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $3.02
Upside: +893.38%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $17.63
Upside: +3,121.78%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $391.36
Upside: -28.20%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.83
Upside: +182.69%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $0.95
Upside: +10,208.19%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $273.09
Upside: +8.02%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $110.86
Upside: -22.42%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $31.99
Upside: +50.05%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $6.95
Upside: +331.65%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $36.72
Upside: +96.08%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.23
Upside: +306.50%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $83.90
Upside: +19.19%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $197.24
Upside: +1.91%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $59.69
Upside: +42.40%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $12.52
Upside: +155.59%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $18.10
Upside: +1,098.90%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $19.39
Upside: +147.55%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $15.60
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $461.24
Upside: -66.61%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $53.94
Upside: +115.05%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $4.52
Upside: +2,245.13%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.27
Upside: +128.20%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $210.04
Upside: -60.96%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $397.97
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.54
Upside: -